Header Logo

Connection

JAFFER A AJANI to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications JAFFER A AJANI has written about Antineoplastic Agents.
JAFFER A AJANI
Connection Strength
3.215
Antineoplastic Agents
  1. HERIZON-GEA-01: Zanidatamab + chemo?? tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022 Sep; 18(29):3255-3266.
    View in: PubMed
    Score: 0.175
  2. Targeting Angiogenesis in Colorectal Carcinoma. Drugs. 2019 Jan; 79(1):63-74.
    View in: PubMed
    Score: 0.136
  3. Early versus Delayed Therapy of Advanced Gastric Cancer Patients--Does It Make a Difference? Oncology. 2015; 89(4):215-20.
    View in: PubMed
    Score: 0.107
  4. Biologics in combination with chemotherapy for gastric cancer: is this the answer? Expert Opin Pharmacother. 2015 May; 16(7):955-60.
    View in: PubMed
    Score: 0.105
  5. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013 Nov; 10(11):643-55.
    View in: PubMed
    Score: 0.094
  6. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013 Apr; 15(2):146-51.
    View in: PubMed
    Score: 0.091
  7. Advanced gastroesophageal carcinoma: an update on the current therapeutic landscape. Onkologie. 2012; 35(4):204-9.
    View in: PubMed
    Score: 0.085
  8. Therapy: localized gastric cancer--a CLASSIC shift in the paradigm? Nat Rev Gastroenterol Hepatol. 2012 Mar 06; 9(4):194-5.
    View in: PubMed
    Score: 0.085
  9. An expert opinion on esophageal cancer therapy. Expert Opin Pharmacother. 2011 Feb; 12(2):225-39.
    View in: PubMed
    Score: 0.078
  10. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. Biomark Med. 2010 Aug; 4(4):535-41.
    View in: PubMed
    Score: 0.076
  11. Multimodality approaches to localized gastric cancer. J Natl Compr Canc Netw. 2010 Apr; 8(4):417-25.
    View in: PubMed
    Score: 0.074
  12. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer. 2008 Sep 15; 113(6):1302-8.
    View in: PubMed
    Score: 0.067
  13. Molecular determinants of prognosis in oesophageal cancer patients treated with chemoradiation. Br J Cancer. 2008 Oct 07; 99(7):1195; author reply 1196.
    View in: PubMed
    Score: 0.066
  14. Therapy of localized esophageal cancer: it is time to reengineer our investigative strategies. Onkologie. 2008 Jul; 31(7):360-1.
    View in: PubMed
    Score: 0.065
  15. Emerging drugs in the treatment of advanced gastric cancer. Expert Opin Emerg Drugs. 2008 Mar; 13(1):135-44.
    View in: PubMed
    Score: 0.064
  16. Current treatment for localized anal carcinoma. Curr Opin Oncol. 2007 Jul; 19(4):396-400.
    View in: PubMed
    Score: 0.061
  17. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 01; 13(1):234-40.
    View in: PubMed
    Score: 0.059
  18. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs. 2006 Sep; 24(5):441-6.
    View in: PubMed
    Score: 0.058
  19. Gastric and gastro-oesophageal cancer therapy. Expert Opin Pharmacother. 2005 Dec; 6(16):2805-12.
    View in: PubMed
    Score: 0.055
  20. Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S78-81.
    View in: PubMed
    Score: 0.055
  21. Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005; 10 Suppl 3:49-58.
    View in: PubMed
    Score: 0.051
  22. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist. 2024 Apr 04; 29(4):e514-e525.
    View in: PubMed
    Score: 0.049
  23. Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies. Cancer Immunol Res. 2022 Dec 02; 10(12):1441-1461.
    View in: PubMed
    Score: 0.045
  24. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002 Feb 01; 94(3):641-6.
    View in: PubMed
    Score: 0.042
  25. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis. Ann Surg. 2021 10 01; 274(4):544-548.
    View in: PubMed
    Score: 0.041
  26. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 5):52-4.
    View in: PubMed
    Score: 0.039
  27. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma. Mol Oncol. 2020 06; 14(6):1410-1426.
    View in: PubMed
    Score: 0.037
  28. A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J. 2000 Mar-Apr; 6(2):78-81.
    View in: PubMed
    Score: 0.037
  29. Adjuvant therapy for gastric carcinoma: closing out the century. Oncology (Williston Park). 1999 Nov; 13(11):1485-94; discussion 1497-502 passim.
    View in: PubMed
    Score: 0.036
  30. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020 01; 69(1):18-31.
    View in: PubMed
    Score: 0.035
  31. Recent developments in oral chemotherapy options for gastric carcinoma. Drugs. 1999; 58 Suppl 3:85-90.
    View in: PubMed
    Score: 0.034
  32. Chemotherapy for gastric carcinoma: new and old options. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):44-7.
    View in: PubMed
    Score: 0.033
  33. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol. 1998 Aug; 16(8):2877-85.
    View in: PubMed
    Score: 0.033
  34. Current status of therapy for advanced gastric carcinoma. Oncology (Williston Park). 1998 Aug; 12(8 Suppl 6):99-102.
    View in: PubMed
    Score: 0.033
  35. Current status of new drugs and multidisciplinary approaches in patients with carcinoma of the esophagus. Chest. 1998 Jan; 113(1 Suppl):112S-119S.
    View in: PubMed
    Score: 0.032
  36. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. Am J Clin Oncol. 1997 Dec; 20(6):573-6.
    View in: PubMed
    Score: 0.031
  37. Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. Int J Radiat Oncol Biol Phys. 2017 11 01; 99(3):660-666.
    View in: PubMed
    Score: 0.031
  38. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc. 2018 01; 32(1):512.
    View in: PubMed
    Score: 0.031
  39. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017 05; 18(5):640-653.
    View in: PubMed
    Score: 0.030
  40. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Am J Clin Pathol. 2016 Dec; 146(6):647-669.
    View in: PubMed
    Score: 0.029
  41. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer. 2016 10 11; 115(8):974-982.
    View in: PubMed
    Score: 0.029
  42. Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets. Ann Surg Oncol. 2016 11; 23(12):3786-3791.
    View in: PubMed
    Score: 0.029
  43. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. Oncotarget. 2015 Sep 22; 6(28):25883-96.
    View in: PubMed
    Score: 0.027
  44. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg. 2015 Jul; 221(1):83-90.
    View in: PubMed
    Score: 0.026
  45. Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. J Infus Chemother. 1995; 5(3):104-11.
    View in: PubMed
    Score: 0.026
  46. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol. 1994 Aug; 21(4):474-82.
    View in: PubMed
    Score: 0.025
  47. Phase II study of merbarone (NSC 336628) in patients with advanced gastric carcinoma. Cancer Invest. 1994; 12(5):488-90.
    View in: PubMed
    Score: 0.024
  48. Adjuvant radiotherapy and chemotherapy for biliary and pancreatic cancer. Ann Oncol. 1994; 5 Suppl 3:75-80.
    View in: PubMed
    Score: 0.024
  49. High dose external beam radiation therapy with or without concomitant chemotherapy for esophageal carcinoma. Ann Oncol. 1994; 5 Suppl 3:9-15.
    View in: PubMed
    Score: 0.024
  50. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol. 2011 Aug 20; 29(24):3328-30.
    View in: PubMed
    Score: 0.020
  51. Celebrate or calibrate? We say calibrate. J Clin Oncol. 2011 Jul 01; 29(19):2732; author reply 2732-3.
    View in: PubMed
    Score: 0.020
  52. Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer. 1991 Jan 01; 67(1 Suppl):260-5.
    View in: PubMed
    Score: 0.019
  53. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010 Sep 01; 116(17):4007-13.
    View in: PubMed
    Score: 0.019
  54. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. J Natl Cancer Inst. 2010 Apr 21; 102(8):547-56.
    View in: PubMed
    Score: 0.018
  55. A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. Cancer Invest. 1990; 8(6):619-21.
    View in: PubMed
    Score: 0.018
  56. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990; 8(2):147-59.
    View in: PubMed
    Score: 0.018
  57. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2009 Feb; 13(1):49-59.
    View in: PubMed
    Score: 0.017
  58. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer. 2009 Feb 01; 115(3):624-30.
    View in: PubMed
    Score: 0.017
  59. New pharmacological developments in the treatment of hepatocellular cancer. Drugs. 2009; 69(18):2533-40.
    View in: PubMed
    Score: 0.017
  60. In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. Invest New Drugs. 1988 Jun; 6(2):79-85.
    View in: PubMed
    Score: 0.016
  61. Upper gastrointestinal tumors: current status and future perspectives. Expert Rev Anticancer Ther. 2008 Jun; 8(6):975-91.
    View in: PubMed
    Score: 0.016
  62. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2008 Jul; 12(3):253-68.
    View in: PubMed
    Score: 0.016
  63. Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus. 2008; 21(7):575-81.
    View in: PubMed
    Score: 0.016
  64. A randomized study of two schedules of copovithane in patients with advanced colorectal carcinoma. Am J Clin Oncol. 1987 Apr; 10(2):139-40.
    View in: PubMed
    Score: 0.015
  65. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res. 2007 Feb 01; 13(3):912-9.
    View in: PubMed
    Score: 0.015
  66. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer. 2007 Jan 01; 109(1):33-40.
    View in: PubMed
    Score: 0.015
  67. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin Oncol. 2006 Dec; 33(6 Suppl 11):S2-5.
    View in: PubMed
    Score: 0.015
  68. In vitro cytotoxicity patterns of standard and investigational agents on human bone marrow granulocyte-macrophage progenitor cells. Br J Cancer. 1986 Oct; 54(4):607-13.
    View in: PubMed
    Score: 0.015
  69. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer. 2006 Aug 15; 107(4):676-85.
    View in: PubMed
    Score: 0.014
  70. Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer. 2006 Aug 21; 95(4):450-6.
    View in: PubMed
    Score: 0.014
  71. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs. 2006 Jul; 24(4):353-7.
    View in: PubMed
    Score: 0.014
  72. Current progress of cancer chemotherapy The Fifteenth International Symposium of the Hiroshima Cancer Seminar, October 2005. Cancer Sci. 2006 Apr; 97(4):328-31.
    View in: PubMed
    Score: 0.014
  73. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol. 2006 Mar; 1(3):252-9.
    View in: PubMed
    Score: 0.014
  74. Phase II study of spirogermanium in patients with advanced colorectal carcinoma. Invest New Drugs. 1986; 4(4):383-5.
    View in: PubMed
    Score: 0.014
  75. Pharmacogenetics in esophageal cancer. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S87-9.
    View in: PubMed
    Score: 0.014
  76. Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro. Exp Hematol. 1985; 13 Suppl 16:95-100.
    View in: PubMed
    Score: 0.013
  77. Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer. 2005; 36(2):69-76.
    View in: PubMed
    Score: 0.013
  78. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004 Jul 15; 22(14):2918-26.
    View in: PubMed
    Score: 0.012
  79. Phase I trial of pentamethylmelamine. Cancer Treat Rep. 1982 May; 66(5):1227-8.
    View in: PubMed
    Score: 0.011
  80. The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. Mol Cancer Ther. 2019 08; 18(8):1439-1450.
    View in: PubMed
    Score: 0.009
  81. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018 05 03; 9(1):1777.
    View in: PubMed
    Score: 0.008
  82. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol. 1998 Feb; 170(2):339-44.
    View in: PubMed
    Score: 0.008
  83. Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via?Integrin Signaling. Gastroenterology. 2018 04; 154(5):1524-1537.e6.
    View in: PubMed
    Score: 0.008
  84. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World J Surg. 1995 Mar-Apr; 19(2):216-20.
    View in: PubMed
    Score: 0.007
  85. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol. 2014 Aug; 45(2):567-74.
    View in: PubMed
    Score: 0.006
  86. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Ann Oncol. 1994 Mar; 5(3):286-7.
    View in: PubMed
    Score: 0.006
  87. A phase II study of merbarone in patients with adenocarcinoma of the pancreas. Cancer Invest. 1993; 11(6):667-9.
    View in: PubMed
    Score: 0.006
  88. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol. 1992 Dec; 15(6):524-7.
    View in: PubMed
    Score: 0.006
  89. Phase II study of didemnin B in advanced colorectal cancer. Invest New Drugs. 1992 Aug; 10(3):211-3.
    View in: PubMed
    Score: 0.005
  90. Phase II trial of fazarabine in advanced colorectal carcinoma. Invest New Drugs. 1992 Apr; 10(1):39-42.
    View in: PubMed
    Score: 0.005
  91. Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs. 1991 Nov; 9(4):353-6.
    View in: PubMed
    Score: 0.005
  92. Histologic observations and P-glycoprotein expression in gastric and esophageal adenocarcinomas treated with preoperative chemotherapy. Arch Pathol Lab Med. 1991 Aug; 115(8):807-12.
    View in: PubMed
    Score: 0.005
  93. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol. 2010 Dec 01; 28(34):5061-6.
    View in: PubMed
    Score: 0.005
  94. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 2009 Feb 20; 27(6):857-71.
    View in: PubMed
    Score: 0.004
  95. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008 Sep; 32(9):1404-11.
    View in: PubMed
    Score: 0.004
  96. Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):741-7.
    View in: PubMed
    Score: 0.004
  97. Comparison between clinical response and in vitro drug sensitivity of primary human tumors in the adhesive tumor cell culture system. J Clin Oncol. 1987 Dec; 5(12):1912-21.
    View in: PubMed
    Score: 0.004
  98. Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system: an in vitro method of screening new drugs. Eur J Cancer Clin Oncol. 1987 Oct; 23(10):1469-76.
    View in: PubMed
    Score: 0.004
  99. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res. 2006 Nov 01; 12(21):6565-72.
    View in: PubMed
    Score: 0.004
  100. Phase I clinical study of nafazatrom. Invest New Drugs. 1986; 4(3):251-5.
    View in: PubMed
    Score: 0.003
  101. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 01; 61(3):656-64.
    View in: PubMed
    Score: 0.003
  102. Survival of human bone marrow cells after in vitro treatment with 12 anticancer drugs and implications for tumor drug sensitivity assays. J Cancer Res Clin Oncol. 1985; 109(2):130-4.
    View in: PubMed
    Score: 0.003
  103. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res. 1984 Aug; 44(8):3608-12.
    View in: PubMed
    Score: 0.003
  104. Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res. 1987 Jan 15; 47(2):403-6.
    View in: PubMed
    Score: 0.001
  105. The human tumor stem cell assay revisited. Int J Cell Cloning. 1985 Mar; 3(2):116-28.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.